Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAS siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, Intravenous, Intravitreal, Parenteral
01
Overview
FAS siRNA refers to small interfering RNA (siRNA) designed to target and silence the expression of the Fas cell surface death receptor (Fas, CD95, APO-1). Fas is a member of the tumor necrosis factor receptor superfamily that plays a critical role in programmed cell death (apoptosis). By post-transcriptionally silencing Fas expression, FAS siRNA inhibits Fas-mediated apoptotic pathways, thereby protecting cells from death receptor-induced apoptosis. This therapeutic approach has been investigated in preclinical models for various conditions, including acute liver failure, non-alcoholic steatohepatitis (NASH), diabetic retinopathy, type 1 diabetes, myocardial ischemia-reperfusion injury, and intervertebral disc degeneration.
- Other names
- Fas siRNAFas small interfering RNAsiRNA targeting FAS
02
Targets
CASP10 (Caspase-10)CASP3 (Caspase-3)FADDTNFR (TNF receptor family)FASLG (Fas ligand)
Beyond the preview
Go deeper on FAS siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAS siRNA.